Emcure and Gennova to resume mRNA collaboration with HDT
May 30, 2024
Source: drugdu
92
Emcure Pharmaceuticals and its biotech subsidiary, Gennova Biopharmaceuticals have amicably resolved all legal disputes with HDT Bio Corporation. The litigation between them, including before US courts and the arbitral tribunal in London, has been settled and dismissed. Gennova and HDT, who previously collaborated on the successful development of Gennova’s mRNA Covid-19 vaccines, will once again collaborate on the development and commercialisation of mRNA vaccines.
The parties have entered into a long-term agreement to develop mRNA vaccines against a broad range of infectious diseases, in India and several other countries. As part of their agreement, HDT has granted a license to Gennova to use HDT’s patented mRNA vaccine technology in multiple fields.
https://www.business-standard.com/companies/news/emcure-gennova-settle-legal-dispute-with-us-based-hdt-bio-sign-agreement-124052300762_1.html
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- $1.4 billion deal highlights the future of Alzheimer’s disease therapy November 5, 2024
- Johnson&Johnson announces latest personnel changes November 5, 2024
- Sonavex announces completion of new round of financing November 5, 2024
- Breaking news, Johnson & Johnson Medical Global Vice President resigns November 5, 2024
- COVID-19 drugs have become a “dark horse” November 5, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
